Case 18 Medpace Holdings

Medpace Holdings is a global full-service clinical contract research organization (CRO), which offers all phases of clinical development services to the biotechnology, pharmaceutical, and medical device industries. Medpace is involved in the mission of development of safe and effective medical therapeutics across major segments such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and antiviral. Medpace is headquartered in Cincinnati, Ohio. By September 2022, the company employed about 5000 people across 40 countries. The company is one of the world’s leading clinical contract research organizations by revenue. The company offers an operating model of full-service Phase I–IV clinical development services. CROs provide a comprehensive range of product development services for Phase I–IV clinical trials. The company generate fees through the performance of services specified in the customer contracts. The contract scope and pricing are based on either a fixed fee or unit of service model which includes services offered by third parties. The company conduct clinical trials across all major therapeutic areas such as Oncology, Metabolic Disease, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). The average growth rate of revenues and net income was 18% and 36% during the period 2018–2021.